28
Participants
Start Date
July 11, 2017
Primary Completion Date
May 12, 2022
Study Completion Date
August 26, 2024
Pembrolizumab
200 mg/m2, IV (in the vein) on day 1 every three weeks (Weeks 1, 3, 7, 10, 13, 16 and 19). until progression or unacceptable toxicity develops.
Cisplatin
35 mg/m2, IV (in the vein) every week for six weeks.
Radiotherapy
2.00Gy once daily for 32 fractions, 5 fractions/week over six weeks and two days (a total of 64Gy).
Prince of Wales Hospital, Randwick
Chris O'Brien Lifehouse, Camperdown
Royal North Shore Hospital, St Leonards
Liverpool Hospital, Liverpool
Peter MacCallum Cancer Centre, Melbourne
Austin Health, Heidelberg
Sir Charles Gairdner Hospital, Nedlands
Peter MacCallum Cancer Centre, Australia
OTHER
Australian and New Zealand Urogenital and Prostate Cancer Trials Group
OTHER